Cardiotonic Agents Market Report 2026

The cardiotonic agents market size has grown rapidly in recent years. It will grow from $3.11 billion in 2025 to $3.5 billion in 2026 at a compound annual growth rate (CAGR) of 12.3%. The growth in the historic period can be attributed to rising incidence of heart failure, reliance on inotropic support in critical care, limited alternatives for acute cardiac output improvement, expansion of cardiac surgery procedures, hospital-centric cardiovascular treatment.

The cardiotonic agents market size is expected to see rapid growth in the next few years. It will grow to $5.56 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to aging global population, increasing advanced heart failure cases, demand for rapid-acting cardiac drugs, expansion of critical care infrastructure, improved monitoring in cardiac intensive care. Major trends in the forecast period include continued use of cardiotonic drugs in acute heart failure, preference for hospital-based intravenous administration, ongoing demand for digitalis glycosides in arrhythmia, integration of cardiotonic agents in surgical cardiac care, gradual shift toward combination cardiovascular therapy.

The increasing prevalence of cardiovascular diseases is expected to drive the growth of the cardiotonic agents market in the coming years. Cardiovascular diseases (CVDs) are a group of disorders affecting the heart and blood vessels, including coronary artery disease, heart failure, arrhythmias, and stroke. This rise is largely attributed to unhealthy diets high in saturated fats, trans fats, salt, and added sugars, which contribute to obesity, high blood pressure, and elevated cholesterol levels. Cardiotonic agents enhance the efficiency and contraction strength of the heart muscle, supporting better blood circulation and alleviating symptoms associated with various cardiovascular conditions. For example, in September 2023, the World Health Organization, a Switzerland-based intergovernmental organization, reported 17.9 million deaths from cardiovascular diseases. Consequently, the growing prevalence of cardiovascular diseases is fueling the expansion of the cardiotonic agents market.

Leading companies in the cardiotonic agents market are focusing on developing innovative products, such as short-term inotropic drugs, to enhance cardiac performance in acute heart failure and cardiogenic shock. Short-term inotropic drugs temporarily improve the heart’s ability to contract, thereby increasing cardiac output. For example, in June 2023, Hikma Pharmaceuticals plc, a UK-based pharmaceutical company, launched Dobutamine Injection, USP, in a 250 mg/20 mL vial. This injection is intended for short-term inotropic support in adults experiencing cardiac decompensation due to reduced heart contractility, commonly resulting from heart disease or following cardiac surgery. Dobutamine works by stimulating beta-1 receptors, enhancing heart muscle contractility and cardiac output with a rapid onset of 1-2 minutes. The injection is administered intravenously, typically in a hospital setting under close monitoring.

In April 2023, SK Capital Partners LP, a US-based capital markets firm, acquired Apotex Pharmaceutical Holdings Inc. for an undisclosed amount. Through this acquisition, SK Capital aims to accelerate Apotex’s growth and innovation by leveraging its expertise to expand global access to affordable, high-quality pharmaceuticals. Apotex Pharmaceutical Holdings Inc., based in Canada, manufactures a cardiotonic agent under the brand name Apo-Digoxin.

Major companies operating in the cardiotonic agents market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Fresenius Kabi, Aurobindo Pharma Limited, Hikma Pharmaceuticals PLC, Alchem International Private Ltd, Farbe Firma Private Limited, Salius Pharma Pvt. Ltd., Johnlee Pharmaceuticals Pvt. Ltd., Healthy Life Pharma Pvt Ltd, Anwita Drugs, Varion Lifesciences, Deccan Nutraceuticals Pvt. Ltd.

North America was the largest region in the cardiotonic agents market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiotonic agents market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiotonic agents market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have affected the cardiotonic agents market by increasing the cost of imported APIs and injectable formulations used in hospital-based cardiovascular care. These impacts are most evident in intravenous cardiotonic drugs, particularly in North America and Europe where global API sourcing is common. Asia-Pacific manufacturers have faced supply chain volatility and pricing pressure due to trade barriers. However, tariffs have supported localized manufacturing of essential cardiac injectables, strengthening domestic supply chains.

The cardiotonic agents market research report is one of a series of new reports that provides cardiotonic agents market statistics, including cardiotonic agents industry global market size, regional shares, competitors with a cardiotonic agents market share, detailed cardiotonic agents market segments, market trends and opportunities, and any further data you may need to thrive in the cardiotonic agents industry. This cardiotonic agents market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cardiotonic agents are drugs that enhance the efficiency and contraction of the heart muscle, improving its ability to pump blood. They are used to treat heart failure and certain arrhythmias by increasing cardiac output and supporting circulation.

The main types of cardiotonic agents include digitalis glycosides, phosphodiesterase inhibitors, cardioprotectants, sympathomimetic agents, and others. Digitalis glycosides are compounds derived from the Digitalis plant that increase the force of heart contractions and help regulate heart rhythm. These drugs can be administered orally, intravenously, or through other routes, with dosage forms including tablets, solutions, and more. They are applied in various medical situations, such as cardiac surgeries, atrial fibrillation, heart failure, and pulmonary hypertension, and are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The cardiotonic agents market consists of sales of digoxin, milrinone, dobutamine, levosimendan, and amrinone. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.